Why the study?
Do NOACs alter organ-specific bleeding patterns compared to VKAs in patients with non-valvular atrial fibrillation?
Do NOACs alter organ-specific bleeding patterns compared to VKAs in patients with non-valvular atrial fibrillation?
NOACs provide similar efficacy to warfarin in non-valvular AF but present a distinct organ-specific bleeding profile, notably reducing intracranial hemorrhage while potentially increasing gastrointestinal bleeding.
Answers are grounded in this paper and cite their sources.
Supports NOAC use in NVAF for lower ICH risk; confirms efficacy parity but leaves GI bleeding agent-specific questions open.
Anticoagulants are effective at preventing and treating thrombosis, but can cause bleeding. For decades, vitamin K antagonists (VKAs) have been the only available oral anticoagulants. The development of non-VKA oral anticoagulants (NOACs), which inhibit either factor Xa or thrombin stoichiometrically, has provided alternatives to VKAs for several indications. The results of recent large-scale randomised controlled trials comparing NOACs with VKAs for the prevention of stroke in patients with non-valvular atrial fibrillation (AF) have produced some unexpected results. As a group, NOACs showed similar efficacy as warfarin, but a reduced risk of major bleeding. The reduction in bleeding with NOACs was greatest with intracranial hemorrhage. In contrast, the relative risk of gastro-intestinal bleeding was increased with some NOACs. In this review, we explore the potential mechanisms as well as the implications of these organ-specific bleeding patterns.
No takes yet. Share an insight, caveat, or question.
Vanassche et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: